Dendritic cell-based cancer immunotherapy for colorectal cancer

World J Gastroenterol. 2016 May 7;22(17):4275-86. doi: 10.3748/wjg.v22.i17.4275.


Colorectal cancer (CRC) is one of the most common cancers and a leading cause of cancer-related mortality worldwide. Although systemic therapy is the standard care for patients with recurrent or metastatic CRC, the prognosis is extremely poor. The optimal sequence of therapy remains unknown. Therefore, alternative strategies, such as immunotherapy, are needed for patients with advanced CRC. This review summarizes evidence from dendritic cell-based cancer immunotherapy strategies that are currently in clinical trials. In addition, we discuss the possibility of antitumor immune responses through immunoinhibitory PD-1/PD-L1 pathway blockade in CRC patients.

Keywords: Cancer immunotherapy; Colorectal cancer; Cytotoxic T lymphocyte; Dendritic cell; Immune-checkpoint inhibitors.

Publication types

  • Review

MeSH terms

  • B7-H1 Antigen / antagonists & inhibitors
  • Carcinoembryonic Antigen / immunology
  • Colorectal Neoplasms / immunology
  • Colorectal Neoplasms / therapy*
  • Dendritic Cells / immunology*
  • Humans
  • Immunotherapy / methods*
  • Melanoma-Specific Antigens / immunology
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • T-Lymphocytes, Cytotoxic / immunology
  • WT1 Proteins / immunology


  • B7-H1 Antigen
  • CD274 protein, human
  • Carcinoembryonic Antigen
  • MAGEA1 protein, human
  • Melanoma-Specific Antigens
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • WT1 Proteins
  • WT1 protein, human